CN107217088B - Ankylosing spondylitis microbial markers - Google Patents
Ankylosing spondylitis microbial markers Download PDFInfo
- Publication number
- CN107217088B CN107217088B CN201610165176.1A CN201610165176A CN107217088B CN 107217088 B CN107217088 B CN 107217088B CN 201610165176 A CN201610165176 A CN 201610165176A CN 107217088 B CN107217088 B CN 107217088B
- Authority
- CN
- China
- Prior art keywords
- ankylosing spondylitis
- marker
- species
- bifidobacterium
- abundance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010002556 Ankylosing Spondylitis Diseases 0.000 title claims abstract description 212
- 230000000813 microbial effect Effects 0.000 title claims abstract description 35
- 244000005700 microbiome Species 0.000 claims abstract description 128
- 239000003550 marker Substances 0.000 claims abstract description 89
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 14
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 14
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 12
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 12
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 11
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 claims abstract description 11
- 241000186361 Actinobacteria <class> Species 0.000 claims abstract description 8
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 7
- 241000222355 Trametes versicolor Species 0.000 claims description 2
- 241000131482 Bifidobacterium sp. Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 52
- 241001208869 Bifidobacterium sp. 12_1_47BFAA Species 0.000 abstract description 5
- 241000302534 Actinomyces sp. ICM47 Species 0.000 abstract description 3
- 241000186216 Corynebacterium Species 0.000 abstract description 3
- 241000894007 species Species 0.000 description 76
- 238000012163 sequencing technique Methods 0.000 description 40
- 230000000968 intestinal effect Effects 0.000 description 28
- 239000003814 drug Substances 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 230000009286 beneficial effect Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 9
- 238000012795 verification Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000011231 Crohn disease Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000606125 Bacteroides Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 4
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000853331 Eggerella Species 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- 241000605956 Fusobacterium mortiferum Species 0.000 description 2
- 101150027568 LC gene Proteins 0.000 description 2
- 241001112693 Lachnospiraceae Species 0.000 description 2
- 241001531296 Muricidae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001480182 Acidia Species 0.000 description 1
- 241001147825 Actinomyces sp. Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000962922 Clostridium sp. L2-50 Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000531155 Pectobacterium Species 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The invention discloses a ankylosing spondylitis microbial marker, which consists of the following microorganisms: actinomycetes (Actinomyces sp.icm47), Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium (Bifidobacterium sp.12_1_47BFAA), Bifidobacterium longum (Bifidobacterium longum), corynebacterium aerogenes (collinella aerociens), Bifidobacterium bifidum (Bifidobacterium bifidum) and Bifidobacterium pseudocatenulatum (Bifidobacterium pseudocatenulatum). Also discloses a method and a device for determining the state of an individual by using the ankylosing spondylitis microbial marker. Compared with the healthy population, the named ankylosing spondylitis marker is obviously enriched in the ankylosing spondylitis patient population and can be used as a distinguishing marker for the healthy population and the ankylosing spondylitis patient population.
Description
Technical Field
The invention relates to the field of biomarkers, in particular to an ankylosing spondylitis microbial marker, and more particularly relates to an ankylosing spondylitis marker, application of the ankylosing spondylitis marker, a method for determining the state of an individual by using the ankylosing spondylitis marker, a device for determining the state of the individual by using the ankylosing spondylitis marker, a method for classifying a plurality of individuals by using the ankylosing spondylitis marker, a medicine for treating ankylosing spondylitis and a method for preparing the medicine for treating ankylosing spondylitis.
Background
Ankylosing Spondylitis (AS) is a chronic progressive inflammatory disease that mainly invades the spine and involves the sacroiliac and peripheral joints. The disease is mostly male with 15-30 years old, the ratio of male to female is 2: 1-3: 1, the cause of ankylosing spondylitis is not completely clear before research shows, and the research results in recent years show that the disease is related to genetic predisposition, infection, immunity and other factors.
Ankylosing spondylitis is usually insidious in onset and has no clinical symptoms in the early stage, and some patients can show mild general symptoms in the early stage, such as hypodynamia, emaciation, long-term or intermittent low fever, anorexia, mild anemia and the like. Because of the mild condition, most patients cannot find the disease early, so that the condition is delayed and the optimal treatment time is lost.
Ankylosing spondylitis is closely related to human leukocyte antigen HLA-B27, according to epidemiological investigation, the positive rate of HLA-B27 of ankylosing spondylitis patients is as high as 90-96%, while the positive rate of HLA-27 of common people is only 4-9%; the incidence rate of ankylosing spondylitis of HLA-B27 positive people is about 10% -20%, while the incidence rate of common people is 1-2 per mill, and the difference is about 100 times. Although the HLA-B27 test is helpful for diagnosis of ankylosing spondylitis, most patients are diagnosed by medical history, signs and X-ray examination. At present, the early diagnosis of ankylosing spondylitis is mainly examined by imaging such as CT, radioactive nuclear scanning, magnetic resonance and the like, and the examination process is complex.
With the completion of human genome sequencing and the high-speed development of high-throughput sequencing technology, gene screening becomes the direction of ankylosing spondylitis diagnosis, and has advantages for discovering groups with potential ankylosing spondylitis. Studies have shown that more than 70% of ankylosing spondylitis patients suffer from intestinal inflammation, and 5-10% of these patients have severe intestinal inflammation and may develop clinical Inflammatory Bowel Disease (IBD) or Crohn's Disease (CD) (miellants et al, 1985). Some marker genes for Crohn's Disease (CD) are associated with ankylosing spondylitis (Parkes et al, 2013), suggesting that both diseases may have similar pathogenesis, possibly associated with gut disorders. Studies have shown that multiple genes associated with ankylosing spondylitis play an important role in gut immunity, such as genes involved in the interleukin IL-23 pathway, in regulating gut health (Wellcome et al, 2007). Compared to healthy controls, ankylosing spondylitis patients and their orthotopic intestinal permeability is increased, again illustrating the important role of intestinal microbes in ankylosing spondylitis (miellents et al, 1991). To date, there are no reports of intestinal microbial markers for patients with ankylosing spondylitis.
Disclosure of Invention
The present invention aims to solve at least one of the above technical problems to some extent or at least to provide a commercial choice.
According to a first aspect of the present invention, there is provided a microbial marker for ankylosing spondylitis, the marker consisting of the following microorganisms: actinomycetes (Actinomyces sp.icm47), Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium (Bifidobacterium sp.12_1_47BFAA), Bifidobacterium longum (Bifidobacterium longum), corynebacterium aerogenes (collinella aerociens), Bifidobacterium bifidum (Bifidobacterium bifidum) and Bifidobacterium pseudocatenulatum (Bifidobacterium pseudocatenulatum).
The microbial marker for ankylosing spondylitis provided by the invention is determined by comparative analysis and verification of differences of abundances of microorganisms in stool samples of a large number of individuals suffering from ankylosing spondylitis and a large number of healthy control individuals, and the microbial marker related to ankylosing spondylitis in intestinal microorganisms is determined. The method can determine the probability of an individual in a ankylosing spondylitis state or a healthy state by using the named ankylosing spondylitis marker, and can be used for non-invasive early discovery or auxiliary detection of ankylosing spondylitis.
According to a second aspect of the present invention, the present invention provides the use of the above-mentioned ankylosing spondylitis microbial marker in detecting ankylosing spondylitis, monitoring treatment of ankylosing spondylitis, preparation of a medicament for treating ankylosing spondylitis and/or preparation of a functional food.
The ankylosing spondylitis microbial marker is determined by analyzing the abundance of various intestinal microorganisms in stool samples of ankylosing spondylitis disease groups and healthy groups through difference comparison and verifying a large number of stool samples in known states. The ankylosing spondylitis marker is significantly enriched in patients with ankylosing spondylitis compared with the healthy group, and the significant enrichment refers to that the abundance of various microorganisms contained in the ankylosing spondylitis marker is statistically significantly higher or obviously and substantially higher than that in the healthy group compared with that in the healthy group. The substance capable of reducing the abundance of the substance can be used for treating the ankylosing spondylitis or beneficial to patients with the ankylosing spondylitis to take, the substance capable of reducing the abundance of the substance is not limited to a medicament for treating the ankylosing spondylitis and a functional food beneficial to intestinal flora balance, and the ankylosing spondylitis marker provided by the invention can be used for preparing a medicament for treating the ankylosing spondylitis and/or preparing a functional food, a health-care medicament and the like beneficial to intestinal flora balance.
According to a third aspect of the present invention, there is provided a method of determining the status of an individual using the aforementioned ankylosing spondylitis microbial marker, the method comprising: (1) determining the abundance of various microorganisms in the ankylosing spondylitis marker in a stool sample of the individual; (2) comparing the abundances of the various microorganisms in the ankylosing spondylitis marker determined in (1) with those in a control group consisting of stool samples of one or more groups of individuals of the same state, the state including suffering from ankylosing spondylitis and not suffering from ankylosing spondylitis, respectively, and determining the state of the individual according to the obtained comparison result. The ankylosing spondylitis marker is determined by analyzing the abundance of various intestinal microorganisms in stool samples of ankylosing spondylitis disease groups and healthy groups through difference comparison and verifying a large number of stool samples in known states.
The method of the aspect of the invention is based on detecting the abundance of various microorganisms in the ankylosing spondylitis microorganism marker in the stool sample of the individual, respectively comparing the detected abundance of various microorganisms with the abundance of the microorganisms in the control group, and determining the probability that the individual is an ankylosing spondylitis individual or a healthy individual according to the obtained comparison result. Provides a non-invasive auxiliary detection method for early detection of ankylosing spondylitis.
All or a part of the steps of the method for determining the state of an individual using the ankylosing spondylitis microbial markers according to the aspect of the present invention described above may be performed using an apparatus/system including the respective unit function modules detachably, or the method may be programmed, stored in a machine-readable medium, and executed by a machine.
According to a fourth aspect of the present invention, there is provided an apparatus for determining a state of an individual using the aforementioned ankylosing spondylitis microbial marker, the apparatus being adapted to perform all or part of the steps of the method of determining a state of an individual using ankylosing spondylitis microbial markers according to an aspect of the present invention, the apparatus comprising: a data input unit for inputting data; a data output unit for outputting data; a processor for executing an executable program, the executing of the executable program comprising performing all or a portion of the steps of the above-described method for determining a status of an individual using ankylosing spondylitis; and the storage unit is connected with the data input unit, the data output unit and the processor and is used for storing data, wherein the storage unit comprises the executable program. The above description of the technical features and advantages of the method for determining the status of an individual using ankylosing spondylitis microbial markers according to an aspect of the present invention is equally applicable to the device according to this aspect of the present invention, and will not be described herein again.
According to a fifth aspect of the present invention, there is provided a system for determining a state of an individual using the aforementioned ankylosing spondylitis microbial marker, the system being adapted to perform all or part of the steps of the method for determining a state of an individual using ankylosing spondylitis microbial markers according to an aspect of the present invention, the system comprising: a microorganism abundance determination unit for determining the abundance of various microorganisms in the ankylosing spondylitis marker in a stool sample of the individual; and an individual state determination unit for respectively comparing the abundances of various microorganisms in the ankylosing spondylitis marker from the microorganism abundance determination unit with the abundances of the microorganisms in a control group, and determining the state of the individual according to the obtained comparison result, wherein the control group consists of one or more groups of stool samples of individuals in the same state, and the state comprises the state with ankylosing spondylitis and the state without ankylosing spondylitis. The above description of the technical features and advantages of the method for determining the status of an individual using ankylosing spondylitis markers according to an aspect of the present invention is equally applicable to the system according to this aspect of the present invention, and will not be repeated herein.
According to a sixth aspect of the present invention, there is provided a method of classifying a plurality of individuals using the aforementioned ankylosing spondylitis microbial marker, the method comprising: determining the state of each individual by using the method for determining the state of the individual according to the aspect of the invention; and classifying the individuals according to the obtained states of the individuals. The method can distinguish a plurality of individuals or a plurality of unknown stool samples according to different states of the individuals, and is convenient for classification and marking management. In addition, the above description of the technical features and advantages of the method for determining the status of an individual using the ankylosing spondylitis microbial marker of one aspect of the present invention is equally applicable to the method of this aspect of the present invention, and will not be repeated herein.
According to a seventh aspect of the present invention, there is provided a medicament for treating ankylosing spondylitis, which causes a decrease in the abundance of each of the microorganisms in the aforementioned ankylosing spondylitis microorganism markers. The ankylosing spondylitis microbial marker is determined by differential analysis of abundance of various intestinal microbes in stool samples of ankylosing spondylitis disease groups and healthy groups and verification of a large number of stool samples in known states. Compared with the healthy group, the ankylosing spondylitis marker is remarkably enriched in the ankylosing spondylitis disease group, and the remarkable enrichment refers to that the abundance of various microorganisms contained in the ankylosing spondylitis marker is statistically significantly higher or obviously and substantially higher than that in the healthy group. The substance with reduced abundance can be used for treating ankylosing spondylitis or beneficial to patients with ankylosing spondylitis, and can be used as a medicine for treating ankylosing spondylitis.
The medicament or the functional food of the invention reasonably and effectively applies the determined ankylosing spondylitis microbial marker, supports the growth of beneficial bacteria in the intestinal tract and/or inhibits potential pathogenic bacteria in the intestinal tract, and has important significance for assisting in reducing the blood endotoxin level and/or relieving the clinical symptoms of ankylosing spondylitis.
According to an eighth aspect of the present invention, there is provided a method for preparing or screening a medicament for treating ankylosing spondylitis according to one aspect of the present invention described above, comprising the step of preparing or screening a substance capable of inducing a decrease in the abundance of each of the microorganisms in the ankylosing spondylitis marker according to one aspect of the present invention described above as the medicament.
By utilizing the method for producing or screening the medicament for treating the ankylosing spondylitis, disclosed by the invention, the determined ankylosing spondylitis biomarker is reasonably and effectively applied to screening, so that the medicament capable of supporting the growth of beneficial bacteria in an intestinal tract and/or inhibiting potential pathogenic bacteria in the intestinal tract can be obtained, and the method has important significance for assisting in reducing the blood endotoxin level and/or relieving the clinical symptoms of the ankylosing spondylitis.
Drawings
The above and/or additional aspects and advantages of the present invention will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
FIG. 1 is a schematic illustration of the experimental analysis procedure for screening and identifying the microbial markers of ankylosing spondylitis in an example of the present invention.
Fig. 2 is a schematic diagram showing the results of AUC evaluation of a microbial species marker as a diagnostic index in the example of the present invention.
Detailed Description
Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are illustrative only for the purpose of explaining the present invention, and are not to be construed as limiting the present invention. It should be noted that the terms "first" or "second", etc. are used herein for convenience of description only and are not to be construed as indicating or implying any relative importance or order between them.
In the description of the present invention, "a plurality" means two or more unless otherwise specified. In this document, unless expressly stated or limited otherwise, the terms "connected" and "connected" are to be construed broadly, e.g., as meaning either a fixed connection or a removable connection or an integral connection; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements.
A biological marker is a cellular, biochemical or molecular change that can be detected from a biological medium. Biological media include various body fluids, tissues, cells, feces, hair, breath, and the like.
The abundance of a certain microorganism refers to the abundance of that microorganism in a certain population of microorganisms, for example, the abundance of that microorganism in a population of gut microorganisms, and can be expressed as the amount of that microorganism in that population.
The identity (identity) and similarity (similarity) of sequences are referred to as the degree of identity or similarity, respectively, between sequences.
According to one embodiment of the invention, the ankylosing spondylitis biomarker is provided, and the detection of the change of the biomarker can determine the relative probability that an individual suffers from ankylosing spondylitis. The ankylosing spondylitis microbial marker consists of the following microorganisms: actinomycetes (Actinomyces sp.ICMs 47), Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium sp.12_1_47BFAA, Bifidobacterium longum (Bifidobacterium longum), Coriolus versicolor (Collinsela aerofaciens), Bifidobacterium bifidum (Bifidobacterium bifidum) and Bifidobacterium pseudocatenulatum (Bifidobacterium pseudocatenulatum).
The microbial marker for ankylosing spondylitis is determined by differential comparative analysis and verification of the abundance of microbes in fecal samples of a large number of ankylosing spondylitis individuals and a large number of healthy control individuals, and the microbial marker related to ankylosing spondylitis in intestinal microbes is determined. The probability that an individual is in the ankylosing spondylitis state or in the healthy state can be determined by using the ankylosing spondylitis marker, and the method can be used for non-invasive early discovery, auxiliary detection of ankylosing spondylitis and the like.
According to one embodiment of the invention, the provided ankylosing spondylitis microbial marker is used for detecting ankylosing spondylitis, monitoring and treating ankylosing spondylitis, preparing medicines for treating ankylosing spondylitis and/or preparing functional foods. The microbial marker of ankylosing spondylitis is determined by analyzing the abundance of various intestinal microorganisms in stool samples of ankylosing spondylitis disease groups and healthy groups through difference comparison by the inventor and verifying a large number of stool samples in known states. Compared with the healthy population group, the ankylosing spondylitis microbial marker is remarkably enriched in the ankylosing spondylitis disease group, and the remarkable enrichment refers to that the abundance of various microorganisms contained in the ankylosing spondylitis marker is statistically meaningfully higher or is remarkably and substantially higher than that in the healthy group.
The substance capable of reducing the abundance of the named ankylosing spondylitis marker can be used for treating ankylosing spondylitis or beneficial to patients with ankylosing spondylitis to take, the substance capable of reducing the abundance of the named ankylosing spondylitis marker is not limited to a medicine for treating ankylosing spondylitis and a functional food beneficial to intestinal flora balance, and the ankylosing spondylitis marker provided by the embodiment can be used for preparing a medicine for treating ankylosing spondylitis and/or preparing a functional food, a health-care medicine and the like beneficial to intestinal flora balance.
According to another embodiment of the present invention, there is provided a method for determining the status of an individual using the ankylosing spondylitis marker of the above embodiment, the method including the following steps (1) and (2):
(1) determining abundance of ankylosing spondylitis microbial markers in individuals to be testedAnd (4) degree.
Determining the abundance of various microorganisms in the ankylosing spondylitis microorganism markers in the stool sample of the individual to be tested.
According to an embodiment of the invention, the following is performed to accomplish this step: obtaining sequencing data for a nucleic acid sequence in a fecal sample of the individual, the sequencing data comprising a plurality of reads; aligning the reads to genomes of various microorganisms in the markers to obtain alignment results; determining the abundance of each microorganism in the marker according to the comparison result.
The sequencing data is obtained by sequencing nucleic acid sequences in a sample, and the sequencing can be selected from but not limited to semiconductor sequencing technology platforms such as PGM, Ion Proton and BGISEQ-100 platforms, synthetic sequencing technology platforms such as Hiseq and Miseq sequence platforms of Illumina and single molecule real-time sequencing platforms such as PacBio sequence platform according to different selected sequencing platforms. The sequencing mode can be single-ended sequencing or double-ended sequencing, and the obtained off-machine data are sequencing and reading fragments which are called reads (reads).
The alignment can be performed by using known alignment software, such as SOAP, BWA, TeraMap, etc., in the alignment process, the alignment parameters are generally set, one or a pair of reads (reads) is set to allow at most s base mismatches (mismatches), for example, s is set to be less than or equal to 2, and if more than s bases in the reads are mismatched, it is considered that the reads cannot be aligned (aligned) to the assembled fragment. The obtained alignment result includes the alignment of each read with the genome of each species, including information as to whether the read can align with the genome of a certain species or species, uniquely align with only one species or with the genomes of multiple species, align with the position of the genome of a species, align with unique position or multiple positions of the genome of a species, and the like. According to one embodiment of the invention, alignment was performed using SOAPalign 2.21 with the setting parameter-r 2-m 100-x 1000.
The genome of the microorganism refers to a predetermined sequence of the species of the microorganism, and may be any reference template of a biological category to which a sample to be tested belongs or contains, which is obtained in advance, for example, the target is the microorganism in the sample to be tested, the reference sequence may be a reference genome of various microorganisms in an NCBI database and/or a DACC enteric genome disclosed in HMP and MetaHIT projects, and further, a resource library containing more reference sequences may be configured in advance, for example, a more similar sequence is selected or determined to be assembled as the reference sequence according to factors such as the state of an individual from which the sample to be tested is derived, a region, and the like. According to one embodiment of the invention, reference genomes for various microorganisms are obtained from public databases, typically, reference genomes for a microorganism in multiple versions, i.e., a microorganism in multiple public genomes.
reads are aligned to the reference genome of the species, which can be divided into two parts: a) unique reads (U): uniquely aligning the genome of the previous species; these reads are referred to as unique reads. That is, if the genomes on the reads alignments are from the same species, the reads are defined as unique reads. b) Multiple reads (M): aligning the genomes of more than one species, defined as multiple reads. That is, if the genomes on the reads alignments are from at least two species, these reads are defined as multiple reads.
According to one embodiment of the invention, said determining the abundance of each microorganism in said marker from the alignment results according to sequencing data comprises determining the abundance of microorganism species S using the following formula: abundance of microbial species S Ab (S) ═ Ab (us) + Ab (ms), where Ab (U)S)＝US/lS，USFor the unique alignment of the number of reads of this species of microorganism S,/STo compare the length of the genome of this species of microorganism S,
MSfor the number of reads of this species of microorganism S in the non-unique alignment, i denotes the number of reads of this species of microorganism S in the non-unique alignment, CoiThe abundance coefficients corresponding to reads i of this species of microorganism S are not uniquely aligned,
n is the number of species of the microorganism in the read alignment of the microorganism S in the non-unique alignment, j is the number of species in the read alignment of the microorganism S in the non-unique alignment, UjNumber of reads for microbial species j being the only alignment.
For a given microbial species S, the abundance is Ab (S), in relation to the Unique reads and Multiple reads, Ab (U) and Ab (M) in the above formulas are the abundances contributed by the Unique reads and Multiple reads, respectively, of that species S. Each multiple read has a specific species abundance coefficient Co, and assuming that one multiple read is aligned to the top N species, the Co of the multiple read can be calculated using the following formula:
that is, for such multiple reads, the sum of the abundances of unique reads of the N species to which they are aligned is used as the denominator.
(2) Abundance comparisons to determine individual status.
Comparing the abundances of the various microorganisms in the ankylosing spondylitis marker determined in (1) with those in a control group consisting of stool samples of one or more groups of individuals of the same state, respectively, the state including a state with ankylosing spondylitis and a healthy state, and determining the state of the individual according to the obtained comparison result. The ankylosing spondylitis marker is determined by analyzing the abundance of various intestinal microorganisms in stool samples of ankylosing spondylitis disease groups and healthy groups through difference comparison and verifying a large number of stool samples in known states.
The abundance of each microorganism in the marker in the control group may be determined simultaneously with or sequentially with the individual to be tested. According to one embodiment of the present invention, the abundance of each microorganism in the marker in the control group is pre-determined and stored as a basis for setting the threshold. And comparing the abundance of the microorganisms in the marker in the sample of the individual to be tested with a threshold value, and determining the state of the individual to be tested based on the difference degree of the two. The threshold may be a value or range of values, for example, based on the mean abundance of a microorganism in a control group, the corresponding threshold for that microorganism may be set to a 95% confidence interval of the mean abundance.
According to an embodiment of the present invention, the control group consists of stool samples of a plurality of individuals with ankylosing spondylitis, and the step (2) includes: determining the individual as suffering from ankylosing spondylitis when the abundance of each microorganism in the ankylosing spondylitis marker determined in step (1) is not different from that in the control group. According to an embodiment of the invention, the indifference is that the abundance of each microorganism in the ankylosing spondylitis marker from the microorganism abundance determining unit falls within a first predetermined confidence interval of its abundance in the control group, optionally the first predetermined confidence interval is a 95% confidence interval.
The term non-difference is said to mean that the abundance of each microorganism in the ankylosing spondylitis marker determined in step (1) falls within a first predetermined confidence interval of its abundance in the control group. The confidence interval is referred to as the estimation interval of the overall parameter constructed from the sample statistics. In statistics, the Confidence interval (Confidence interval) of a probability sample is an interval estimate for some overall parameter of this sample. The confidence interval exhibits the extent to which the true value of this parameter has a certain probability of falling around the measurement. The confidence interval indicates the degree of plausibility of the measured value of the measured parameter, i.e. the "certain probability" required above. This probability is called the confidence level.
According to an embodiment of the invention, the control group consists of stool samples from a plurality of healthy individuals, the step (2) comprising: when the abundance of each microorganism in the ankylosing spondylitis marker determined in step (1) is not different from that in the control group, determining that the individual is in a state without ankylosing spondylitis. Said no difference is that the abundance of each microorganism in the ankylosing spondylitis marker identified in (1) falls within a second predetermined confidence interval of its abundance in the control group, optionally said second predetermined confidence interval is a 95% confidence interval.
It should be noted that, depending on the purpose or requirement, there may be different requirements on the confidence level of the result of determining the state of an individual, and a person skilled in the art may choose different significance levels (α), i.e. different probabilities of making errors, such that the confidence level of the determined state of an individual is 1- α. For example, it is reliable to determine that the individual is 95% in the determined state using this embodiment.
The method is based on detecting the abundance of various microorganisms in the ankylosing spondylitis marker in an individual stool sample, respectively comparing the detected and determined abundances of various microorganisms with the abundances of various microorganisms in a control group, and determining the probability that the individual is an ankylosing spondylitis individual or a healthy individual according to the obtained comparison result. Provides a non-invasive auxiliary detection or auxiliary intervention treatment method for early detection of ankylosing spondylitis.
All or part of the steps of the method for determining the state of an individual using a ankylosing spondylitis marker in any one of the above embodiments may be performed using an apparatus/system including detachable function modules of respective units, or the method may be programmed, stored in a machine-readable medium, and executed by a machine.
According to an embodiment of the present invention, there is provided an apparatus for determining a state of an individual using the ankylosing spondylitis marker in the above-described embodiment of the present invention, the apparatus being configured to perform all or part of the steps of the method for determining a state of an individual using the ankylosing spondylitis marker in the above-described embodiment of the present invention, the apparatus including: a data input unit for inputting data; a data output unit for outputting data; a processor for executing an executable program, the executing of the executable program comprising performing the method for determining the status of an individual according to one embodiment of the present inventors; and the storage unit is connected with the data input unit, the data output unit and the processor and is used for storing data, wherein the storage unit comprises the executable program. The above description of the technical features and advantages of the method for determining the status of an individual using ankylosing spondylitis markers in any embodiment of the present invention is also applicable to the apparatus of the present invention, and will not be repeated herein.
According to an embodiment of the present invention, there is provided a system for determining the status of an individual using the ankylosing spondylitis marker in the above-described embodiment of the present invention, the apparatus being configured to perform all or part of the steps of the method for determining the status of an individual using the ankylosing spondylitis marker in any of the above-described embodiments of the present invention, the system including: a microorganism abundance determination unit for determining the abundance of various microorganisms in the ankylosing spondylitis marker in a stool sample of the individual; and an individual state determination unit for respectively comparing the abundances of various microorganisms in the ankylosing spondylitis marker from the microorganism abundance determination unit with the abundances of the microorganisms in a control group, and determining the state of the individual according to the obtained comparison result, wherein the control group consists of one or more groups of stool samples of individuals in the same state, and the state comprises the state with ankylosing spondylitis and the state without ankylosing spondylitis. The above description of the technical features and advantages of the method for determining the status of an individual using ankylosing spondylitis markers in any of the embodiments of the invention applies equally to the system of this aspect of the invention.
According to an embodiment of the present invention, the microbial abundance determination unit is configured to perform the following: obtaining sequencing data for a nucleic acid sequence in a fecal sample of the individual, the sequencing data comprising a plurality of reads; aligning the reads to genomes of various microorganisms in the markers to obtain alignment results; determining the abundance of each microorganism in the marker according to the comparison result.
The sequencing data is obtained by sequencing nucleic acid sequences in a sample, and the sequencing can be selected from but not limited to semiconductor sequencing technology platforms such as PGM, Ion Proton and BGISEQ-100 platforms, synthetic sequencing technology platforms such as Hiseq and Miseq sequence platforms of Illumina and single molecule real-time sequencing platforms such as PacBio sequence platform according to different selected sequencing platforms. The sequencing mode can be single-ended sequencing or double-ended sequencing, and the obtained off-machine data are sequencing and reading fragments which are called reads (reads).
The alignment can be performed by using known alignment software, such as SOAP, BWA, TeraMap, etc., in the alignment process, the alignment parameters are generally set, one or a pair of reads (reads) is set to allow at most s base mismatches (mismatches), for example, s is set to be less than or equal to 2, and if more than s bases in the reads are mismatched, it is considered that the reads cannot be aligned (aligned) to the assembled fragment. The obtained alignment result includes the alignment of each read with the genome of each species, including information as to whether the read can align with the genome of a certain species or species, uniquely align with only one species or with the genomes of multiple species, align with the position of the genome of a species, align with unique position or multiple positions of the genome of a species, and the like. According to one embodiment of the invention, alignment was performed using SOAPalign 2.21 with the setting parameter-r 2-m 100-x 1000.
The genome of the microorganism refers to a predetermined sequence of the species of the microorganism, and may be any reference template of a biological category to which a sample to be tested belongs or contains, which is obtained in advance, for example, the target is the microorganism in the sample to be tested, the reference sequence may be a reference genome of various microorganisms in an NCBI database and/or a DACC enteric genome disclosed in HMP and MetaHIT projects, and further, a resource library containing more reference sequences may be configured in advance, for example, a more similar sequence is selected or determined to be assembled as the reference sequence according to factors such as the state of an individual from which the sample to be tested is derived, a region, and the like. According to one embodiment of the invention, reference genomes for various microorganisms are obtained from public databases, typically, reference genomes for a microorganism in multiple versions, i.e., a microorganism in multiple public genomes.
reads are aligned to the reference genome of the species, which can be divided into two parts: a) unique reads (U): uniquely aligning the genome of the previous species; these reads are referred to as unique reads. That is, if the genomes on the reads alignments are from the same species, the reads are defined as unique reads. b) Multiple reads (M): aligning the genomes of more than one species, defined as multiple reads. That is, if the genomes on the reads alignments are from at least two species, these reads are defined as multiple reads.
According to one embodiment of the invention, said determining the abundance of each microorganism in said marker from the alignment results according to sequencing data comprises determining the abundance of microorganism species S using the following formula: abundance of microbial species S Ab (S) ═ Ab (U)S)+Ab(MS) Wherein, Ab (U)S)＝US/lS，USFor the unique alignment of the number of reads of this species of microorganism S,/STo compare the length of the genome of this species of microorganism S,
MSfor the number of reads of this species of microorganism S in the non-unique alignment, i denotes the number of reads of this species of microorganism S in the non-unique alignment, CoiThe abundance coefficients corresponding to reads i of this species of microorganism S are not uniquely aligned,
n is the number of species of the microorganism in the read alignment of the microorganism S in the non-unique alignment, j is the number of species in the read alignment of the microorganism S in the non-unique alignment, UjNumber of reads for microbial species j being the only alignment.
For a given microbial species S, the abundance is Ab (S), in relation to the Unique reads and Multiple reads, Ab (U) and Ab (M) in the above formulas are the abundances contributed by the Unique reads and Multiple reads, respectively, of that species S. Each multiple read has a specific species abundance coefficient Co, and assuming that one multiple read is aligned to the top N species, the Co of the multiple read can be calculated using the following formula:
that is, for such multiple reads, the sum of the abundances of unique reads of the N species to which they are aligned is used as the denominator.
According to an embodiment of the invention, the control group in the individual status determination unit comprises stool samples of a plurality of individuals with ankylosing spondylitis, the individual status determination unit being adapted to perform the following: determining that the individual has ankylosing spondylitis when the abundance of each microorganism in the ankylosing spondylitis marker from the microorganism abundance determining unit is not different from that in the control group.
According to an embodiment of the invention, the indifference is that the abundance of each microorganism in the ankylosing spondylitis marker from the microorganism abundance determining unit falls within a first predetermined confidence interval of its abundance in the control group, optionally the first predetermined confidence interval is a 95% confidence interval.
According to an embodiment of the invention, the control group in the individual status determination unit comprises stool samples of a plurality of healthy individuals, the individual status determination unit being adapted to perform the following: determining that the individual is not suffering from ankylosing spondylitis when the abundances of the various microorganisms in the ankylosing spondylitis marker from the microorganism abundance determining unit are all not different from the abundances of the various microorganisms in the control group.
According to an embodiment of the invention, the indifference is that the abundance of each microorganism in the ankylosing spondylitis marker from the microorganism abundance determining unit falls within a second predetermined confidence interval of its abundance in the control group, optionally the second predetermined confidence interval is a 95% confidence interval.
According to another embodiment of the present invention, there is provided a method for classifying a plurality of individuals using the ankylosing spondylitis marker according to any one of the above-described embodiments of the present invention, the method including: determining the state of each individual by using the method for determining the state of the individual in any embodiment of the invention; and classifying the individuals according to the obtained states of the individuals. The method can distinguish a plurality of individuals or a plurality of unknown stool samples according to different states of the individuals, and is convenient for classification and marking management. In addition, the above description of the technical features and advantages of the method for determining the state of an individual by using a ankylosing spondylitis marker in any embodiment of the present invention is also applicable to the method of the aspect of the present invention, and will not be repeated herein.
According to still another embodiment of the present invention, there is provided a medicament for treating ankylosing spondylitis, which is capable of inducing a decrease in the abundance of each of the microorganisms in the ankylosing spondylitis marker according to any one of the above-described embodiments of the present invention. The ankylosing spondylitis marker is determined by differential analysis of the abundance of various intestinal microorganisms in stool samples of ankylosing spondylitis disease groups and healthy groups and verification of a large number of stool samples in known states. Compared with the healthy group, the ankylosing spondylitis marker is remarkably enriched in the ankylosing spondylitis disease group, and the remarkable enrichment refers to that the abundance of various microorganisms contained in the ankylosing spondylitis marker is statistically significantly higher or obviously and substantially higher than that in the healthy group. The substance with reduced abundance can be used for treating ankylosing spondylitis or beneficial to patients with ankylosing spondylitis, and can be used as a medicine for treating ankylosing spondylitis.
By utilizing the medicament or the functional food of the embodiment, the determined ankylosing spondylitis microbial marker is reasonably and effectively applied, the growth of intestinal beneficial bacteria is supported and/or intestinal potential pathogenic bacteria are inhibited, the defect of an intestinal barrier can be prevented, the intestinal microecological structure is improved and restored, and the medicament or the functional food has important significance for assisting in reducing the blood endotoxin level and/or relieving the clinical symptoms of ankylosing spondylitis.
According to still another embodiment of the present invention, there is provided a method for preparing or screening a drug for treating ankylosing spondylitis in the above-described embodiment, which includes the step of preparing or screening a substance capable of inducing a decrease in the abundance of each of the microorganisms in the ankylosing spondylitis marker in any of the above-described embodiments of the present invention as the drug.
By using the method for producing or screening the medicament for treating the ankylosing spondylitis in the embodiment of the invention, the medicament capable of supporting the growth of beneficial bacteria in the intestinal tract and/or inhibiting potential pathogenic bacteria in the intestinal tract can be obtained by reasonably and effectively applying the determined ankylosing spondylitis biomarker for screening, the defect of the intestinal tract barrier can be prevented, the microecological structure of the intestinal tract can be improved and recovered, and the method has important significance for assisting in reducing the blood endotoxin level and/or relieving the clinical symptoms of the ankylosing spondylitis.
The method and/or apparatus of the present invention is described in detail below with reference to specific embodiments. Reagents, sequences (linkers, tags, and primers), software, and instruments referred to in the following examples are conventional commercial products or open sources, such as the transcriptome library construction kit from Illumina, unless otherwise submitted.
The following embodiments include a first phase and a second phase, namely a corresponding discovery phase and a verification phase. The discovery phase includes: comparing intestinal microbial composition and functional changes of 73 ankylosing spondylitis patients and 83 healthy control groups based on analysis to determine species markers; the verification phase comprises: the accuracy of the first stage results was verified using 24 AS patients and 31 healthy controls.
Example 1
In this example, the inventors performed a correlation analysis study of the microorganisms of the entire intestinal flora from stool samples of 73 ankylosing spondylitis patients and 83 healthy controls to characterize the fecal microflora and functional components. In summary, the inventors downloaded about 428.09Gb high quality sequencing data (LC healthy people) and 294Gb high quality sequencing data obtained by experimental sequencing to construct the ankylosing spondylitis reference gene set, and constructed a more complete gene set with the downloaded LC gene set and IGC gene set. Metagenomic analysis shows that 17 microbial species are closely related to ankylosing spondylitis diseases, wherein 7 bacteria are enriched in intestinal microorganisms of healthy people, and 10 bacteria are enriched in intestinal microorganisms of patients with ankylosing spondylitis.
1. Acquisition of sequencing data
1.1 sample Collection and DNA extraction
Ankylosing spondylitis patients come from the first subsidiary hospital of the university of traditional Chinese medicine in Hangzhou Zhejiang, and 73 stool samples of ankylosing spondylitis patients in total are collected in experiments, wherein the fresh stool samples of each individual are divided into 200 mg/part and 5 parts in total, and are immediately frozen and stored in a refrigerator at the temperature of-80 ℃.
Total DNA was extracted from fecal samples of 73 patients with ankylosing spondylitis of China. DNA is extracted by a method of extracting DNA by phenol trichloromethane treatment.
1.2 library construction and sequencing, and reference data download
DNA banking was performed according to the instructions of the Instrument manufacturer (Illumina). The library was sequenced by PE100 bp. The Illumina HiSeq2000(Illumina, San Diego, CA) platform sequenced a library of 73 samples. Each sample yielded on average 4.03Gb (sd. + -0.64 Gb) high quality sequencing results, totaling 294Gb sequencing data volume.
Sequencing data for 83 healthy chinese were downloaded from EBI, access No.: ERP 005860.
Referring to the experimental procedure of fig. 1, relevant biomarkers for ankylosing spondylitis were identified, wherein omitted steps or details are well known to those skilled in the art, and several important steps are described as follows.
2. Identification of biomarkers
2.1 basic processing of sequencing data
1) Sequencing data is subjected to quality control: after obtaining the sequencing data of 73 AS samples in the first stage, the AS samples were filtered, and the quality control was performed according to the following criteria: a) (ii) removing reads greater than 50% of the low quality base (Q20); b) removing reads greater than 5N bases; c) the tail low mass (Q20) and N bases were removed. Sequences that miss pairs of reads are considered to be a single read for assembly.
2) The downloaded data of the healthy person is processed as well.
3) LC gene sets were obtained from Qin, N.et al.alternatives of the human gut microorgan imporvo sis.Nature 513,59-64 (2014.) and IGC gene sets were downloaded from ftp:// climb.genomics.cn/pub/10.5524/100001-101000/100064/1. GeneCatalogs/IGC.fa.gz.
2.2 species abundance analysis
The above processed pair-end clean reads were aligned (matched) to a redundant genome using SOAPalign 2.21, here, the so-called redundant genome is from the reference genome of the bacterium disclosed in each database. The alignment parameter is-r 2-m 100-x 1000. Reads aligned to redundant genomes, possibly divided into two parts: a) unique reads (U): reads align the genomes of only the previous species; these reads are defined as unique reads. That is, if the genomes are from the same species, reads are aligned to more than one genome and the inventors define these reads as unique reads. b) Multiple reads (M): if reads align to the genome of more than one species, they are defined as multipleads. That is, if the aligned genomes are from different species, the inventors define these reads as multiple reads.
For species S, the abundance is ab (S), related to the characteristic U reads and shared M reads, and is calculated as follows:
Ab(S)＝Ab(U)+Ab(M)
Ab(U)＝U/l
ab (U) and Ab (M) are the abundance of unique reads and multiple reads from species S, respectively, and l represents the length of the genome. Each multiple reads has a specific species coefficient Co; assuming that a multiple reads aligns to the top N species, Co for the multiple reads is calculated as follows:
for these reads, the inventors normalized the abundance of unique reads of the summed N species. That is, for multiple reads, the inventors used the sum of the abundance of unique reads for the N species against which they were aligned as the denominator.
2.3 Association analysis/screening species markers
In order to obtain the intestinal microbial species marker closely related to the ankylosing spondylitis, the inventor utilizes the abundance data of the intestinal microbial species of two groups of ankylosing spondylitis patients (73 cases) and healthy people (83 cases) to carry out a research on the correlation with diseases at the species level.
Based on the abundance table of species obtained in the above step, the inventors set criteria as follows: (1) the median abundance of the species in the ankylosing spondylitis patient group or healthy human group must be greater than 0.00001; (2) performing a Wilcoxon rank sum test by combining multiple tests of Benjamini Hochberg to obtain a p value and a q value of each species and the relevance of ankylosing spondylitis; (3) a relatively very strict threshold (q _ values <5.0E-05) is used. Then, the inventors obtained 28 intestinal microbial species closely related to ankylosing spondylitis disease. Among them, 14 species were enriched in patients with Ankylosing Spondylitis (AS), and 14 species were enriched in healthy persons (HD). The 28 microbial species markers are shown in table 1 below.
TABLE 1
Example 2
To confirm that the analysis results in example 1 can be used as a ankylosing spondylitis species marker, species abundances of 31 healthy people and 24 ankylosing spondylitis patients in a validation population are further compared, and a final microbial species marker is screened according to validation conditions. The acquisition and processing of the sequencing data of the validation population was performed with reference to example 1.
The verification results are as follows: of the 14 species enriched in healthy people, 7 were verified in the verification set to have high quality (p _ values <0.05), and the p and q values of the markers for microorganism species enriched in healthy people are shown in table 2 below. The microorganism species are, respectively, Muricidae (Lachnospiraceae bacteria 6_1_63FAA), Fusobacterium mortiferum (Fusobacterium mortiferum), Bacteroides ([ Bacteroides ] pectobacterium), Enterobacter cloacae (Enterobacter cloacae), Acidia (Eubacterium elegans), Muricidae (Lachnospiraceae bacteria 8_1_57FAA), and Clostridium (Clostridium sp.L 2-50). Bacteroides are present in the human intestinal tract and primarily help break down food to provide the nutrients and energy needed by the human body.
TABLE 2
For the 14 species enriched in ankylosing spondylitis patients, 10 of them were verified to be of high quality in the verification set (p _ values <0.05), and the cases of p and q values verified for the microbial species markers enriched in ankylosing spondylitis patients are shown in table 3 below, namely actinomycetes (actinomycetes sp.icm), Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium (Bifidobacterium sp.12_1_47BFAA), Bifidobacterium longum (Bifidobacterium longum), corynebacterium aerogenes (collinesiensis), Bifidobacterium bifidum (Bifidobacterium bifidum), Bifidobacterium pseudocatenulatum (Bifidobacterium pseudocatenulatum), eggerella lenta (eggerella lenta), Bifidobacterium catenulatum (Bifidobacterium catenulatum), Bifidobacterium catenulatum (Bifidobacterium bifidum), Bifidobacterium pseudocatenulatum (Bifidobacterium adolescentis), Bifidobacterium longum (Bifidobacterium longum), and Bifidobacterium adolescentis (Bifidobacterium longum).
The Bifidobacterium can prevent diarrhea and reduce constipation, i.e. bidirectional regulation. Research shows that more than 70% of ankylosing spondylitis patients suffer from intestinal inflammation, 5-10% of the patients have severe intestinal inflammation and can develop into clinical Inflammatory Bowel Disease (IBD) or Crohn's Disease (CD) (Mielants et al, 1985), and research shows that bacteroides, clostridia and sclerites in intestinal tracts of IBD patients decrease and the ratio of actinomycetes and proteobacteria increases.
TABLE 3
The inventor thinks that 7 microbial species markers enriched from healthy people can be used as a reverse index for the disease of the ankylosing spondylitis, or used as microbial preparation drug flora components for researching and developing for treating the ankylosing spondylitis, or used as a recovery index for detecting the ankylosing spondylitis and monitoring the treatment process of the ankylosing spondylitis; 10 microorganism species markers enriched for ankylosing spondylitis patients are used as positive indexes for ankylosing spondylitis diseases, and are particularly used for noninvasive detection and diagnosis of ankylosing spondylitis diseases.
The inventor utilizes the 17 microbial species markers to construct a comprehensive index, estimates the area AUC under the ROC (Receiver-operating characteristic) curve, and evaluates the diagnosis capability of the comprehensive index corresponding to the diagnosis capability of the ankylosing spondylitis if the AUC is larger. By evaluating 156 samples in the first stage (first stage) and 55 samples in the second stage (second stage), as shown in fig. 2, the diagnosis ability is very good, the AUC obtained in the first stage is 96.62%, as shown in the left graph of fig. 2, the confidence interval is 93.93% -99.31%; the second phase resulted in an AUC of 89.92% with a confidence interval of 81.28% -98.56% as shown in the right panel of fig. 2.
Example 3
45 stool samples were used for the detection of the individual status of the sample source.
With reference to the method of example 2, the abundances of actinomycetes (Actinomyces sp.icm47), Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium (Bifidobacterium sp.12_1_47BFAA), Bifidobacterium longum (Bifidobacterium longum), corylinus aeroginis (collinesium), Bifidobacterium bifidum (Bifidobacterium bifidum) and Bifidobacterium pseudocatenulatum (Bifidobacterium ruducedanum) in each stool sample were determined, whether the abundances of these seven strains in each sample fall within 95% confidence intervals of the abundances of the disease control group or the healthy control group, and the status of the individual corresponding to the sample in which the abundances of these seven strains fall within the corresponding interval of the disease control group was determined as a ankylosing spondylitis patient, and the status of the individual corresponding to the sample in which the healthy group falls within the corresponding interval of the seven strains was determined as a ankylosing spondylitis patient.
The result shows that the method can judge the individual state of 41 samples, and the judgment of the state of the individual corresponding to 38 samples in the 41 samples is consistent with the recorded state of the individual from which the sample is derived.
In addition, the inventors found that the combined detection of the species in table 2 and table 3, for example, the detection of the enrichment of the species markers in table 3, and the non-enrichment of the species markers in table 2, can more accurately determine and find the ankylosing spondylitis patients or susceptible people.
In the scheme of treating ankylosing spondylitis by using the markers, the inventors found that the growth of the species markers in 3 is inhibited or eliminated, and the species markers in table 2 are enriched, so that the treatment effect is excellent.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
While embodiments of the invention have been shown and described, it will be understood by those of ordinary skill in the art that: various changes, modifications, substitutions and alterations can be made to the embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the claims and their equivalents.
Claims (1)
1. A microbial ankylosing spondylitis marker, characterized in that the marker consists of the following microorganisms:
actinomycetes sp.strainaicM47, Bifidobacterium breve, Bifidobacterium sp.strainan 12_1_47BFAA, Bifidobacterium longum, Bifidobacterium brenesium, Coriolus versicolor, Bifidobacterium bifidum, and Bifidobacterium pseudocatenulatum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610165176.1A CN107217088B (en) | 2016-03-22 | 2016-03-22 | Ankylosing spondylitis microbial markers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610165176.1A CN107217088B (en) | 2016-03-22 | 2016-03-22 | Ankylosing spondylitis microbial markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107217088A CN107217088A (en) | 2017-09-29 |
| CN107217088B true CN107217088B (en) | 2020-08-11 |
Family
ID=59928019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610165176.1A Active CN107217088B (en) | 2016-03-22 | 2016-03-22 | Ankylosing spondylitis microbial markers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107217088B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108148906A (en) * | 2018-02-23 | 2018-06-12 | 古洁若 | A kind of ankylosing spondylitis enteric microorganism marker and its application |
| CN108877937A (en) * | 2018-05-02 | 2018-11-23 | 广州元亿国际生物科技有限公司 | A kind of method and apparatus that medical information is generated according to Tiny ecosystem testing result |
| CN114410809A (en) * | 2021-12-08 | 2022-04-29 | 上海金翌生物科技有限公司 | Slow-transmission constipation marker microorganism and application thereof |
| CN114317784B (en) * | 2021-12-08 | 2024-02-13 | 上海锐翌医学检验实验室有限公司 | Behcet disease marker microorganism and application thereof |
| CN114292932A (en) * | 2021-12-31 | 2022-04-08 | 上海金翌生物科技有限公司 | Chronic transport constipation marker KO and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104195146A (en) * | 2014-07-15 | 2014-12-10 | 浙江大学 | Microbial marker of liver cirrhosis, and application |
| CN104540962A (en) * | 2012-08-01 | 2015-04-22 | 深圳华大基因研究院 | Biomarkers for diabetes and usages thereof |
| CN105296590A (en) * | 2015-09-30 | 2016-02-03 | 上海锐翌生物科技有限公司 | Colorectal cancer marker and application thereof |
| CN105368944A (en) * | 2015-11-23 | 2016-03-02 | 广州基迪奥生物科技有限公司 | Biomarker capable of detecting diseases and application of biomarker |
-
2016
- 2016-03-22 CN CN201610165176.1A patent/CN107217088B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104540962A (en) * | 2012-08-01 | 2015-04-22 | 深圳华大基因研究院 | Biomarkers for diabetes and usages thereof |
| CN104195146A (en) * | 2014-07-15 | 2014-12-10 | 浙江大学 | Microbial marker of liver cirrhosis, and application |
| CN105296590A (en) * | 2015-09-30 | 2016-02-03 | 上海锐翌生物科技有限公司 | Colorectal cancer marker and application thereof |
| CN105368944A (en) * | 2015-11-23 | 2016-03-02 | 广州基迪奥生物科技有限公司 | Biomarker capable of detecting diseases and application of biomarker |
Non-Patent Citations (2)
| Title |
|---|
| Gutmicrobes, immunity, and spondyloarthritis;Stoll ML et al.;《Clinical Immunology》;20150509;第159卷(第2期);摘要，2脊柱关节炎，表1 * |
| Intestinal Dysbiosis in Ankylosing Spondylitis;Costello ME et al.;《ARTHRITIS & RHEUMATOLOGY》;20150331;第67卷(第3期);摘要，结果，图1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107217088A (en) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107217089B (en) | Method and device for determining individual state | |
| CN107217088B (en) | Ankylosing spondylitis microbial markers | |
| CN105132518A (en) | Colon cancer marker and application thereof | |
| CN110838365A (en) | Irritable bowel syndrome related flora marker and kit thereof | |
| CN113913490B (en) | Non-alcoholic fatty liver disease marker microorganism and application thereof | |
| CN114182007B (en) | Behcet disease marker gene and application thereof | |
| CN114381534B (en) | Fatty liver marker microorganism and application thereof | |
| WO2017156739A1 (en) | Isolated nucleic acid application thereof | |
| CN107217086B (en) | Disease marker and application | |
| CN105733988B (en) | Composition and application | |
| CN105671177B (en) | Ankylosing spondylitis marker and application thereof | |
| CN113999922B (en) | Acute diarrhea marker microorganism and application thereof | |
| WO2017156764A1 (en) | Isolated nucleic acid application thereof | |
| CN114836508A (en) | Marker microorganism for chronic obstructive pulmonary disease and application thereof | |
| CN113930479B (en) | Systemic lupus erythematosus marker microorganism and application thereof | |
| CN114317784B (en) | Behcet disease marker microorganism and application thereof | |
| CN114317531B (en) | Salix tenuifolia-origin syndrome marker gene and application thereof | |
| CN113999923B (en) | Microbe for marking syndrome of salix tenuifolia-origin field and application thereof | |
| CN114262743B (en) | Stroke marker microorganism and application thereof | |
| CN114317718A (en) | Rheumatoid arthritis marker KO and application thereof | |
| CN114517235A (en) | Myalgic encephalomyelitis marker gene and application thereof | |
| CN114292932A (en) | Chronic transport constipation marker KO and application thereof | |
| CN114317717A (en) | Crohn's disease marker gene for children and application thereof | |
| CN114381492A (en) | Myalgic encephalomyelitis marker microorganism and application thereof | |
| CN114292933A (en) | Graves disease marker gene and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |